Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes

Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes

Age-related macular degeneration (AMD) affects an estimated 30 million to 50 million people worldwide and is the leading cause of severe vision loss in higher income countries. Neovascular AMD accounts for about 10 per cent of AMD cases, but for about 90 per cent of the severe vision loss that AMD causes. It affects approximately 1.3 per cent of people over 50 years old, with approximately 600,000 new cases of neovascular AMD diagnosed annua Download Supplement - click here

Tags: ocular pathology

Latest Articles

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.